{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:09:25Z","timestamp":1760296165424},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[1998,3,1]],"date-time":"1998-03-01T00:00:00Z","timestamp":888710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[1998,3]]},"DOI":"10.1016\/s0145-2126(97)00160-4","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T22:34:50Z","timestamp":1027636490000},"page":"249-256","source":"Crossref","is-referenced-by-count":19,"title":["Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: Implications for liposome-encapsulated daunorubicin"],"prefix":"10.1016","volume":"22","author":[{"given":"Leo F.","family":"Verdonck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk M.","family":"Lokhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dick J.","family":"Roovers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans G.","family":"van Heugten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0145-2126(97)00160-4_BIB1","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1126\/science.6137059","article-title":"Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines","volume":"221","author":"Kartner","year":"1983","journal-title":"Science"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB2","first-page":"3847","article-title":"Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170- kDa protein detected by photoaffinity labeling","volume":"83","author":"Cornwell","year":"1986"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0092-8674(86)90595-7","article-title":"Internal duplication and homology with bacterial transport proteins in the MDR1 (P-glycoprotein) gene from multidrug-resistant human cells","volume":"47","author":"Chen","year":"1986","journal-title":"Cell"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1365-2141.1990.tb04346.x","article-title":"MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia","volume":"75","author":"Sato","year":"1990","journal-title":"British Journal of Haematology"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB5","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/blood.V78.3.586.586","article-title":"Multidrug resistance (MDR1) gene expression in adult acute leukemias, correlations with treatment outcome and in vitro drug sensitivity","volume":"78","author":"Marie","year":"1991","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/83.10.708","article-title":"MDR1 gene expression and treatment outcome in acute myeloid leukemia","volume":"83","author":"Pirker","year":"1991","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/S0145-2126(97)00160-4_BIB7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood.V79.2.473.473","article-title":"Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis","volume":"79","author":"Campos","year":"1992","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB8","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1182\/blood.V81.9.2394.2394","article-title":"Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia, prognostic implications","volume":"81","author":"Goasguen","year":"1993","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB9","first-page":"6365","article-title":"Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage","volume":"48","author":"Bellamy","year":"1988","journal-title":"Cancer Research"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB10","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1182\/blood.V73.3.747.747","article-title":"Immunohistochemical detection and quantification of P-glycoprotein in multiple drug-resistant human myeloma cells, association with level of drug resistance and drug accumulation","volume":"73","author":"Dalton","year":"1989","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ijc.2910450210","article-title":"Overexpression of the MDR1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthra-cycline accumulation that can be restored by cyclosporin-A","volume":"45","author":"Nooter","year":"1990","journal-title":"International Journal of Cancer"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.V78.1.44.44","article-title":"Multidrug-resistant myeloma, laboratory and clinical effects of verapamil as a chemosensitizer","volume":"78","author":"Salmon","year":"1991","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB13","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1182\/blood.V79.12.3267.3267","article-title":"Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells","volume":"79","author":"Berman","year":"1992","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.1990.tb02650.x","article-title":"Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia","volume":"75","author":"Sonneveld","year":"1990","journal-title":"British Journal of Haematology"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB15","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood.V82.4.1288.1288","article-title":"Enhancement of daunorubicin in accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia","volume":"82","author":"Ross","year":"1993","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB16","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.V83.5.1337.1337","article-title":"Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL","volume":"83","author":"Ross","year":"1994","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/cpt197112196","article-title":"The pharmacokinetics of daunorubicin in man","volume":"12","author":"Alberts","year":"1971","journal-title":"Clin. Pharmacol Ther."},{"key":"10.1016\/S0145-2126(97)00160-4_BIB18","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1200\/JCO.1988.6.5.802","article-title":"Cellular pharmacokinetics of daunorubicin, relationships with the response to treatment in patients with acute myeloid leukemia","volume":"6","author":"Kokenberg","year":"1988","journal-title":"J. Clin Oncol."},{"key":"10.1016\/S0145-2126(97)00160-4_BIB19","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.1992.10.10.1635","article-title":"Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance","volume":"10","author":"Lum","year":"1992","journal-title":"J. Clin Oncol."},{"key":"10.1016\/S0145-2126(97)00160-4_BIB20","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.1992.10.10.1624","article-title":"Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance","volume":"10","author":"Yahanda","year":"1992","journal-title":"J. Clin Oncol."},{"key":"10.1016\/S0145-2126(97)00160-4_BIB21","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.1993.11.9.1652","article-title":"Phase I\/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia","volume":"11","author":"List","year":"1993","journal-title":"J. Clin Oncol."},{"key":"10.1016\/S0145-2126(97)00160-4_BIB22","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1002\/1097-0142(19931215)72:12<3553::AID-CNCR2820721203>3.0.CO;2-B","article-title":"Clinical trials of agents that reverse multidrug resistance. A literature review","volume":"72","author":"Raderer","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB23","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1200\/JCO.1994.12.4.835","article-title":"Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance","volume":"12","author":"Bartlett","year":"1994","journal-title":"J. Clin Oncol."},{"key":"10.1016\/S0145-2126(97)00160-4_BIB24","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.1994.12.8.1584","article-title":"Clinical modulation of multidrug resistance in multiple myeloma, effect of cyclosporine on resistant tumor cells","volume":"12","author":"Sonneveld","year":"1994","journal-title":"J. Clin Oncol."},{"key":"10.1016\/S0145-2126(97)00160-4_BIB25","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1200\/JCO.1990.8.6.1093","article-title":"A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin","volume":"8","author":"Rahman","year":"1990","journal-title":"J. Clin Oncol."},{"key":"10.1016\/S0145-2126(97)00160-4_BIB26","first-page":"3255","article-title":"Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors","volume":"52","author":"Forssen","year":"1992","journal-title":"Cancer Research"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB27","first-page":"2796","article-title":"Initial clinical (phase I) trial of TLC d-99 (doxorubicin encapsulated in liposomes)","volume":"53","author":"Cowens","year":"1993","journal-title":"Cancer Research"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB28","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1200\/JCO.1995.13.4.996","article-title":"Phase I\/II clinical and pharmacokinetic evaluation of liposomal daunorubicine","volume":"13","author":"Gill","year":"1995","journal-title":"J. Clin Oncol."},{"key":"10.1016\/S0145-2126(97)00160-4_BIB29","first-page":"3619","article-title":"Enhancement of murine tumor cell sensitivity to adriamycin by presentation of the drug in phosphatidylcholine-phosphatidylserine liposomes","volume":"50","author":"Fan","year":"1990","journal-title":"Cancer Research"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB30","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/jnci\/84.10.804","article-title":"Increased effectiveness of liposome-encapsulated doxorubicin in multidrug-resistant-transgenic mice compared with free doxorubicin","volume":"84","author":"Mickisch","year":"1992","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0145-2126(97)00160-4_BIB31","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1093\/jnci\/84.24.1909","article-title":"Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells","volume":"84","author":"Rahman","year":"1992","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/S0145-2126(97)00160-4_BIB32","first-page":"1479","article-title":"Antitumour activity of free and liposome-encapsulated annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties","volume":"54","author":"Zou","year":"1994","journal-title":"Cancer Research"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB33","first-page":"5125","article-title":"Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein","volume":"46","author":"Dalton","year":"1986","journal-title":"Cancer Research"},{"issue":"Suppl. 1","key":"10.1016\/S0145-2126(97)00160-4_BIB34","first-page":"252a","article-title":"Correlation of CD34 and multidrug resistance P170 with FAB and cytogenetics but not prognosis in acute myeloid leukemia (AML)","volume":"76","author":"Ball","year":"1990","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB35","first-page":"262","volume":"11","author":"Willman","year":"1992"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB36","first-page":"12","article-title":"Targeted drug delivery","volume":"20","author":"Leyland-Jones","year":"1993"},{"key":"10.1016\/S0145-2126(97)00160-4_BIB37","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/0140-6736(93)91147-E","article-title":"Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma","volume":"341","author":"Presant","year":"1993","journal-title":"Lancet"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212697001604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212697001604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T22:18:44Z","timestamp":1580249924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212697001604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1998,3]]}},"alternative-id":["S0145212697001604"],"URL":"https:\/\/doi.org\/10.1016\/s0145-2126(97)00160-4","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[1998,3]]}}}